Literature DB >> 1384059

Reverse transcriptase of human immunodeficiency virus can use either human tRNA(3Lys) or Escherichia coli tRNA(2Gln) as a primer in an in vitro primer-utilization assay.

L A Kohlstaedt1, T A Steitz.   

Abstract

Although the reverse transcriptase (RT) of human immunodeficiency virus (HIV) uses human tRNA(3Lys) as a primer of viral genome DNA synthesis in vivo, HIV RT binds Escherichia coli glutamine tRNA and in vitro-made human lysine tRNA with nearly equivalent affinities. We show that HIV RT can use either tRNA(3Lys) or tRNA(2Gln) as a primer for DNA synthesis in vitro without the addition of any other host or viral proteins. E. coli tRNA(2Gln) can serve as a primer for HIV RT if a primer-binding site sequence complementary to the 3' end of tRNA(2Gln) is at the 3' end of the template. With this reduced template, the specificity of binding the proper tRNA is due to base-pairing between a bound tRNA to the primer-binding site of the viral RNA template rather than sequence-specific recognition of tRNA(3Lys) by RT. If an 8-nucleotide viral sequence 3' to the primer-binding site is included in the template, then addition of Zn2+ or Co2+ is required for tRNA(3Lys)-primed synthesis, and tRNA(2Gln) now fails to prime synthesis. The latter result implies that a template sequence adjacent to the primer-binding site and containing 6 nucleotides complementary to the anticodon loop of human tRNA(3Lys) plays an active role in tRNA discrimination.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1384059      PMCID: PMC50190          DOI: 10.1073/pnas.89.20.9652

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  16 in total

Review 1.  Retroviral reverse transcriptase: synthesis, structure, and function.

Authors:  S P Goff
Journal:  J Acquir Immune Defic Syndr (1988)       Date:  1990

2.  Active-site zinc ligands and activated H2O of zinc enzymes.

Authors:  B L Vallee; D S Auld
Journal:  Proc Natl Acad Sci U S A       Date:  1990-01       Impact factor: 11.205

3.  Reverse transcriptase mediated binding of primer tRNA to the viral genome.

Authors:  A Araya; L Sarih; S Litvak
Journal:  Nucleic Acids Res       Date:  1979-08-24       Impact factor: 16.971

4.  Protein-RNA interactions in the RNase P holoenzyme from Escherichia coli.

Authors:  A Vioque; J Arnez; S Altman
Journal:  J Mol Biol       Date:  1988-08-20       Impact factor: 5.469

5.  Nucleotide sequence of Rous sarcoma virus.

Authors:  D E Schwartz; R Tizard; W Gilbert
Journal:  Cell       Date:  1983-03       Impact factor: 41.582

6.  Human immunodeficiency virus reverse transcriptase ribonuclease H: specificity of tRNA(Lys3)-primer excision.

Authors:  E S Furfine; J E Reardon
Journal:  Biochemistry       Date:  1991-07-23       Impact factor: 3.162

7.  Interaction of HIV-1 reverse transcriptase with a synthetic form of its replication primer, tRNA(Lys,3).

Authors:  C Barat; S F Le Grice; J L Darlix
Journal:  Nucleic Acids Res       Date:  1991-02-25       Impact factor: 16.971

8.  Overproduction and purification of Escherichia coli tRNA(2Gln) and its use in crystallization of the glutaminyl-tRNA synthetase-tRNA(Gln) complex.

Authors:  J J Perona; R Swanson; T A Steitz; D Söll
Journal:  J Mol Biol       Date:  1988-07-05       Impact factor: 5.469

9.  Characterization of the cDNA synthesized by avian retrovirus reverse transcriptase using 35 S avian myeloblastosis virus RNA and an exogenous bovine primer tRNA.

Authors:  L Sarih; A Araya; S Litvak
Journal:  FEBS Lett       Date:  1988-03-28       Impact factor: 4.124

10.  Small finger protein of avian and murine retroviruses has nucleic acid annealing activity and positions the replication primer tRNA onto genomic RNA.

Authors:  A C Prats; L Sarih; C Gabus; S Litvak; G Keith; J L Darlix
Journal:  EMBO J       Date:  1988-06       Impact factor: 11.598

View more
  38 in total

Review 1.  Viral polymerases.

Authors:  Kyung H Choi
Journal:  Adv Exp Med Biol       Date:  2012       Impact factor: 2.622

2.  A Guide to HIV-1 Reverse Transcriptase and Protease Sequencing for Drug Resistance Studies.

Authors:  Robert W Shafer; Kathryn Dupnik; Mark A Winters; Susan H Eshleman
Journal:  HIV Seq Compend       Date:  2001

Review 3.  Structural insight on processivity, human disease and antiviral drug toxicity.

Authors:  Y Whitney Yin
Journal:  Curr Opin Struct Biol       Date:  2010-12-24       Impact factor: 6.809

4.  Multiple biological roles associated with the Rous sarcoma virus 5' untranslated RNA U5-IR stem and loop.

Authors:  J T Miller; Z Ge; S Morris; K Das; J Leis
Journal:  J Virol       Date:  1997-10       Impact factor: 5.103

5.  pol mutations conferring zidovudine and didanosine resistance with different effects in vitro yield multiply resistant human immunodeficiency virus type 1 isolates in vivo.

Authors:  J J Eron; Y K Chow; A M Caliendo; J Videler; K M Devore; T P Cooley; H A Liebman; J C Kaplan; M S Hirsch; R T D'Aquila
Journal:  Antimicrob Agents Chemother       Date:  1993-07       Impact factor: 5.191

6.  Human immunodeficiency virus type 1 can use different tRNAs as primers for reverse transcription but selectively maintains a primer binding site complementary to tRNA(3Lys).

Authors:  J K Wakefield; A G Wolf; C D Morrow
Journal:  J Virol       Date:  1995-10       Impact factor: 5.103

7.  Reduced replication of human immunodeficiency virus type 1 mutants that use reverse transcription primers other than the natural tRNA(3Lys).

Authors:  A T Das; B Klaver; B Berkhout
Journal:  J Virol       Date:  1995-05       Impact factor: 5.103

8.  Identification of tRNAs incorporated into wild-type and mutant human immunodeficiency virus type 1.

Authors:  M Jiang; J Mak; A Ladha; E Cohen; M Klein; B Rovinski; L Kleiman
Journal:  J Virol       Date:  1993-06       Impact factor: 5.103

9.  Initiation of (-) strand DNA synthesis from tRNA(3Lys) on lentiviral RNAs: implications of specific HIV-1 RNA-tRNA(3Lys) interactions inhibiting primer utilization by retroviral reverse transcriptases.

Authors:  E J Arts; S R Stetor; X Li; J W Rausch; K J Howard; B Ehresmann; T W North; B M Wöhrl; R S Goody; M A Wainberg; S F Grice
Journal:  Proc Natl Acad Sci U S A       Date:  1996-09-17       Impact factor: 11.205

10.  Effects of zidovudine-selected human immunodeficiency virus type 1 reverse transcriptase amino acid substitutions on processive DNA synthesis and viral replication.

Authors:  A M Caliendo; A Savara; D An; K DeVore; J C Kaplan; R T D'Aquila
Journal:  J Virol       Date:  1996-04       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.